Loading
CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination.
Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes clinical 0.97, literature 0.94, genetic association 0.00, somatic mutation 0.82, animal model 0.38). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Basal Cell Carcinoma.
In plain words · CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation.
No product in this corpus aims at CCDC6 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CCDC6: RNA low tissue specificity; high antibody staining in 1 normal tissue. Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Thyroid cancer, Neuroendocrine tumours, Skin cancer (all types)); Open Targets associates it with 2 specific cancer types at or above 0.5 (non-small cell lung carcinoma, medullary thyroid gland carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q16204; IntOGen CCDC6; Human Protein Atlas CCDC6 tissue; Open Targets ENSG00000108091 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Grieco et al, Cell, 1990, "PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas". Source.
Sources: HGNC HGNC:18782 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q16204 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000108091 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.72, thyroid cancer 0.70, neuroendocrine neoplasm 0.63, lung cancer 0.72 (GraphQL API, CC0)); IntOGen CCDC6 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination. Location: Cytoplasm; Cytoplasm, cytoskeleton (UniProt). Locus 10q21.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Bone marrow, Breast, Bronchus, Cerebral cortex, Colon, Duodenum, Esophagus.
No cancer stained high; medium in breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CCDC6" OR ABSTRACT:"CCDC6" OR TITLE:"coiled-coil domain containing 6" OR ABSTRACT:"coiled-coil domain containing 6" OR TITLE:"Coiled-coil domain-containing protein 6" OR ABSTRACT:"Coiled-coil domain-containing protein 6" OR TITLE:"H4" OR ABSTRACT:"H4" OR TITLE:"PTC1" OR ABSTRACT:"PTC1" OR TITLE:"TST1" OR ABSTRACT:"TST1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCDC6, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Lung cancer (all types).
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Open Targets Platform.
Shares Thyroid cancer, Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.